A Phase IIA study using intrathecal treatment of autologous adipose-derived mesenchymal stem cells for amyotrophic lateral sclerosis
Research Grant Recipient: Nathan P. Staff, MD, PhD
Grant Period: 2016-2018
Award Value: $497,086
Site: Mayo Clinic
The overall objective of this proposal is to conduct a multi-site, placebo-controlled Phase IIA clinical trial to obtain clinical data on the safety, efficacy and mechanism of action of intrathecal injection of adipose-derived mesenchymal stem cells as a regenerative therapy for the treatment of the incurable condition, amyotrophic lateral sclerosis.
Dr. Staff is an Assistant Professor of Neurology at Mayo Clinic.